Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy

International Journal of Biological Markers

Volumn 20, Issue 2, 2005, Pages 119-122

  Morote, Juan ^a   Esquena, S ^a   Abascal, J M ^a   Trilla, E ^a   Cecchini, L ^a   Raventos C X ^a   Catalan R ^a   Reventos J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Androgen suppression; Free testosterone; LHRH agonist; Prostate cancer; Serum testosterone

Indexed keywords

ANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CASTRATION; CONTROLLED STUDY; CORRELATION FUNCTION; HORMONE DETERMINATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

EID: 22944458197     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.1427     Document Type: Article

References (9)

1. Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410-3.
2. Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone level and sexual activity in the aging male. BJU International 2002; 89: 526-30.
3. Tsujimura A, Matsumiya K, Matsuoka Y, et al. Bioavailable testosterone with age and erectile dysfunction. J Urol 2003; 170: 2345-7.
4. Morley JE, Patick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002; 51: 554-9.
5. Vermeulen A, Verdonick L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
6. Basaria S, Lieb J, Tang A, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56: 779-86.
7. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and treatment decision algorithm. J Urol 2000; 164: 726-9.
8. Kawakami J, Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonist. J Urol 2002; 167: 288A.
9. Morote J, Esquena S, Abascal JM, et al. Failure to maintain suppressed level of serum testosterone during long acting depot luteinizing hormone releasing hormone agonist therapy in patients with advanced prostate cancer. Eur Urol (submitted).